This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News for AKRO
Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
AKRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat
Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss
Catalyst (CPRX) Rises as Q2 Earnings & Revenues Beat Estimates
Other News for AKRO
Akero Therapeutics: Good Candidate For The MASH Basket
Buy Rating Affirmed for Akero Therapeutics Amid Promising Phase 3 Drug Trial for MASH Treatment
Wellington Management Group LLP's Strategic Acquisition in Akero Therapeutics Inc
Tracking Baker Brothers Portfolio - Q2 2024 Update
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH